Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
about
Bioenergetic profiling of zebrafish embryonic developmentSensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosidesQuinolone-3-diarylethers: a new class of antimalarial drug.Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicityHigh-throughput respirometric assay identifies predictive toxicophore of mitochondrial injury.Screen for small molecules increasing the mitochondrial membrane potential.Biomaterial based cardiac tissue engineering and its applicationsMitochondrial and nuclear genomics and the emergence of personalized medicineMitochondria as a target of environmental toxicants.Metabolic alterations by indoxyl sulfate in skeletal muscle induce uremic sarcopenia in chronic kidney disease.Modulation of mitochondrial bioenergetics in a skeletal muscle cell line model of mitochondrial toxicity.Drug safety testing paradigm, current progress and future challenges: an overview.A PGC-1α-Mediated Transcriptional Network Maintains Mitochondrial Redox and Bioenergetic Homeostasis against Doxorubicin-Induced Toxicity in Human Cardiomyocytes: Implementation of TT21C.Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.Mitochondria and cancer: past, present, and future.Nucleotide Substrate Specificity of Anti-Hepatitis C Virus Nucleoside Analogs for Human Mitochondrial RNA Polymerase.Integrated metabolic models for xenobiotic induced mitochondrial toxicity in skeletal muscle.Mitochondrial dysfunction induced by sertraline, an antidepressant agent.Are meaningful predictions of toxicological outcomes in clinical trials based on in vitro diagnostics of preclinical drug candidates possible?Mitochondrial toxicity assessment in industry--a decade of technology development and insight.Sources, mechanisms, and consequences of chemical-induced mitochondrial toxicity.Mitochondrial Toxicity.High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins
P2860
Q28477289-63CF6708-54FF-476F-8795-D1F32D1C659EQ28485227-30361EA9-E388-44F5-8186-4873E50D7B0CQ34334269-2F50EEAD-E5F6-4A6A-B27A-6886CDD83F4AQ34631498-D42777D3-2785-4280-A588-26BFFF679C5DQ34786843-BDD0A73A-C7CE-4D39-B3BF-D48D6C5E9C80Q34836339-BD7C8876-DB01-4FF0-BF0E-1BFB281EB58CQ35731251-1EC60B61-C15B-40D3-B699-E94924EC202BQ36220588-356B5A68-217D-4E59-9F8F-6B1D7C4E02B2Q36956066-FD2751CA-C25E-446B-9B08-5E65EAC1B30AQ37405600-E30856F5-3428-47E9-AB6B-DC80D6252E58Q37541019-5E038002-2B1E-4792-B01C-2CF13633D29BQ38207946-1346FED8-BA72-499D-85D6-16D1E9DA6CEEQ38802152-C62BD318-C4E0-4601-8DA8-212A02A3CE4AQ39366146-ADD24BD7-70C2-49B0-AF51-34EA520DA7EDQ39448724-CACFC442-AEDC-4C99-922E-C010F36202A6Q40180055-F7373918-2DD9-474A-9106-C87DB51ED199Q42282624-1E7F4F09-770B-49EF-BA4A-3E14317D8C4EQ42720801-1EF6A7E9-C126-4092-AC8A-49DDD07A32A4Q44109819-905BF39D-0652-4CDA-90E0-0E78B2EA4BACQ45223613-2EEFB443-ADAC-45A2-9F55-CE2A7746613FQ47131435-FAABF334-82F7-442E-9A1D-138B0B212707Q47728491-C7E5B365-43A4-4095-AACF-5077682639B2Q58680687-63B68889-6A71-4860-9B81-BF957FAB7501
P2860
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
@en
type
label
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
@en
prefLabel
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
@en
P2093
P2860
P356
P1476
Strategies to reduce late-stage drug attrition due to mitochondrial toxicity.
@en
P2093
James A Dykens
Lisa D Marroquin
Yvonne Will
P2860
P304
P356
10.1586/14737159.7.2.161
P577
2007-03-01T00:00:00Z